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Objectives This study sought to assess the impact of targeted left ventricular (LV) lead placement on outcomes of cardiac
resynchronization therapy (CRT).
Background Placement of the LV lead to the latest sites of contraction and away from the scar confers the best response to CRT. We
conducted a randomized, controlled trial to compare a targeted approach to LV lead placement with usual care.
Methods A total of 220 patients scheduled for CRT underwent baseline echocardiographic speckle-tracking 2-dimensional
radial strain imaging and were then randomized 1:1 into 2 groups. In group 1 (TARGET [Targeted Left Ventricular
Lead Placement to Guide Cardiac Resynchronization Therapy]), the LV lead was positioned at the latest site of
peak contraction with an amplitude of 10% to signify freedom from scar. In group 2 (control) patients under-
went standard unguided CRT. Patients were classified by the relationship of the LV lead to the optimal site as
concordant (at optimal site), adjacent (within 1 segment), or remote (2 segments away). The primary endpoint
was a 15% reduction in LV end-systolic volume at 6 months. Secondary endpoints were clinical response (1
improvement in New York Heart Association functional class), all-cause mortality, and combined all-cause mor-
tality and heart failure–related hospitalization.
Results The groups were balanced at randomization. In the TARGET group, there was a greater proportion of responders
at 6 months (70% vs. 55%, p  0.031), giving an absolute difference in the primary endpoint of 15% (95% con-
fidence interval: 2% to 28%). Compared with controls, TARGET patients had a higher clinical response (83% vs.
65%, p  0.003) and lower rates of the combined endpoint (log-rank test, p  0.031).
Conclusions Compared with standard CRT treatment, the use of speckle-tracking echocardiography to the target LV lead
placement yields significantly improved response and clinical status and lower rates of combined death and
heart failure–related hospitalization. (Targeted Left Ventricular Lead Placement to Guide Cardiac Resynchroniza-
tion Therapy [TARGET] study); ISRCTN19717943) (J Am Coll Cardiol 2012;59:1509–18) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.030Cardiac resynchronization therapy (CRT) reduces both
morbidity and mortality in selected patients with heart
failure who remain symptomatic despite optimal medical
therapy, exhibit intraventricular conduction delay, and have
left ventricular (LV) dysfunction (1–3). However, a signif-
icant proportion of patients fail to achieve benefit from
CRT (4). The position of the LV lead is increasingly
recognized as an important determinant of response to-
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29, 2011, accepted December 3, 2011.gether with mechanical dyssynchrony at baseline and the
extent and distribution of myocardial scar (5–8). The
primary therapeutic target of CRT is restoration of coordi-
nated myocardial contraction, and the current preferred
method to achieve this is to position the LV lead at a lateral
See page 1519
or posterolateral branch of the coronary sinus based on the
results of early hemodynamic studies. Recent reports have
challenged this view and suggest that there is great individ-
ual variation in the optimal LV pacing site and that the
effects of resynchronization may be optimally facilitated
when the left ventricle is paced at the most delayed site
(concordance), avoiding myocardial scar (9–11). Pacing the
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to result in a better clinical re-
sponse, greater LV reverse re-
modeling, and reduced mortality
and heart failure–related hospi-
talization (6,12,13). Similarly,
LV lead placement at areas of
scar is associated with attenuated
clinical and echocardiographic
response (14,15). We report the
findings of a randomized, con-
trolled trial comparing the im-
pact of prospectively targeting the LV lead at the most
delayed viable segment defined by speckle-tracking echo-
cardiography to usual treatment.
Methods
Patient population and study protocol. The TARGET
(Targeted Left Ventricular Lead Placement to Guide Car-
diac Resynchronization Therapy) study was a 2-center,
randomized, controlled trial that enrolled patients between
April 2009 and July 2010. A total of 247 consecutive
patients with advanced heart failure who were eligible for
CRT underwent baseline speckle-tracking echocardiogra-
phy. All patients were in sinus rhythm with impaired LV
systolic function (LV ejection fraction 35%), intraventric-
ular conduction delay (QRS duration 120 ms), and New
York Heart Association (NYHA) functional class III or IV
symptoms despite maximal tolerated optimal medical treat-
ment. In 27 patients (11%), image quality was not suitable
for 2-dimensional (2D) radial strain analysis, and these
patients were therefore excluded. The remaining 220 pa-
tients were randomized in a 1:1 ratio to 1 of 2 groups. In
group 1 (TARGET), an attempt was made to position
the LV lead to the optimal site as defined by 2D radial
strain imaging. In group 2 (control), the patients under-
went standard CRT without echocardiographic guidance.
The study was approved by the local ethics committee,
and the study protocol complied with the guidelines set
out in the Declaration of Helsinki. All participants gave
fully informed written consent, and the trial was regis-
tered on a national database (ISRCTN19717943).
Randomization and masking. Randomization was per-
formed by a computer-generated system, and group assign-
ment used a central fully independent system. Masking was
maintained throughout the study, with all patients in both
groups undergoing the same baseline and follow-up assess-
ments and all assessors of the primary and secondary
endpoints remaining blinded to group assignment.
Baseline assessment. All participants underwent detailed
baseline clinical assessment including a 6-min walk test,
Minnesota Living with Heart Failure Questionnaire, and
echocardiography to ascertain LV volumes and function
before and 6 months after device therapy. Ischemic etiology
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
2D  2-dimensional
LV  left ventricular
LVESV  left ventricular
end-systolic volume
NYHA  New York Heart
Associationwas defined as the presence of coronary stenoses of 50%by invasive coronary angiography. Standard 2D echocardi-
ography was performed using a commercial machine (Vivid 7,
General Electric Medical Systems, Horten, Norway)
equipped with a 3.5-MHz phased-array transducer. The
gray-scale and color Doppler data were acquired in a
cine-loop format and digitally stored for post-processing
offline (EchoPAC, version 7.0, GE Ultrasound, Horten,
Norway). LV end-diastolic volume and left ventricular
end-systolic volume (LVESV) and LV ejection fraction
were calculated using Simpson’s biplane method according
to the guidelines of the American Society of Echocardiog-
raphy (16). Interventricular dyssynchrony was determined as
the difference in time from QRS onset of the continuous
Doppler recordings in the pulmonary and aortic outflow
tracts. Intraventricular dyssynchrony was defined using ra-
dial strain speckle analysis as the delay between the antero-
septal and posterior segments (anteroseptal-posterior wall
delay) using the mid LV short-axis images, and, as previ-
ously reported, a value of 130 ms was considered signifi-
cant (17). All baseline and follow-up clinical and echocar-
diographic data were acquired and analyzed by assessors
blinded to the assigned group and to all other patient-
related data.
Identification of optimal sites for LV pacing. Speckle-
tracking 2D radial strain analysis of the baseline gray-scale
basal and mid LV short-axis was performed in all patients as
previously described (17). The data were made available to
the CRT implanters to guide LV lead placement only in the
TARGET group. All images were recorded with a frame
rate of40 Hz, and the endocardial border was traced using
a point-and-click technique in end-systole followed by
automatic generation of a second larger concentric circle
that was manually adjusted to the epicardium. Speckle-
tracking software automatically analyzed frame-by-frame
movement of the stable patterns of natural acoustic markers
(speckles) to generate time-strain curves over the cardiac
cycle of the 12 nonapical segments. The latest segment of
contraction was identified as the most delayed peak from the
onset of the QRS duration in both the basal and mid
short-axis views. When 1 segment was equally delayed,
then placement of the LV lead at either site was considered
to be concordant. Scar was identified using 2D radial strain
as previously reported (13,18), and those segments with
radial strain amplitude 10% at the LV pacing site were
regarded as nonviable. This figure was chosen based on our
previous work suggesting that this figure has a very high
negative predictive value to identify the presence of scar in
patients being assessed for CRT (19). The optimal pacing
site was therefore defined using both the timing and
amplitude of 2D radial strain in the basal or mid LV
segment with the latest timing to peak contraction and
deformation amplitude of 10% (Fig. 1).
CRT implantation and LV lead placement. LV lead
placement at the coronary sinus was attempted using an
8-French guiding catheter (Easytrak 2/3, Aquity Guidant
Corporation, St. Paul, Minnesota or Attain-SD 4194,
sa
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the control group, this was performed according to standard
clinical practice without echocardiographic guidance, pref-
erentially at a lateral or posterolateral vein. In the TARGET
group, LV lead placement was performed in a 2-step process
at the pre-defined optimal site. First, the coronary venous
anatomy was delineated using balloon occlusive coronary
sinus venography in a steep left anterior oblique orientation
(50° to 90°) such that the coronary sinus encircles the mitral
valve with the tributaries radiating out (20). This left
anterior oblique fluoroscopic image approximates to the
short-axis parasternal echocardiographic view, enabling the
coronary vein that traverses the optimal segment defined by
echocardiography (anterior, lateral, posterior, or inferior
segments) to be readily discernible. The appropriate vein
was then selected by the operator, and an attempt was made
to place the LV lead with due consideration for standard
pacing parameters such as threshold, sensing, and stability.
In all patients, the final position of the LV lead was
determined by an independent assessor blinded to the
echocardiographic data using the post-implantation chest
Figure 1 Speckle-Tracking Echocardiography
to Determine Optimal Sites
Example of echocardiographic speckle-tracking 2-dimensional radial strain
applied to the mid short-axis left ventricle of a single patient with ischemic car-
diomyopathy and previous myocardial infarction to identify optimal pacing sites.
The latest segment of peak contraction is the lateral wall (green line), and left
ventricular (LV) lead placement at this site would ensure a concordant lead.
The peak amplitude of contraction of the anterior wall (light blue) is 10%,
representing an area of scar, and hence this represents a segment to be
avoided for LV lead placement. Significant dyssynchrony is also seen, with the
time delay of peak contraction between the anteroseptum (red line) and poste-
rior wall (purple line) (anteroseptal-posterior wall delay [AS-P]) 130 ms.
Inferoseptum (yellow line), inferior wall (dark blue line). AVC  aortic valve
closure.radiographs and biplane fluoroscopy and categorized aseither basal, mid, or apical in the anteroposterior and right
anterior oblique projections and as anterior, lateral, poste-
rior, or inferior in the left anterior oblique views. The LV
lead was described as concordant if the LV lead paced the
optimal site, adjacent if within 1 segment, or remote if 2
egments from the optimal site. The right ventricular lead
was placed according to operator preference at either the
right ventricular septum or right ventricular apex. The
day after implantation, atrioventricular and interventric-
ular delays were optimized in all patients by echocardi-
ography. Devices were programmed in DDD mode
(lower rate limit, 40) to achieve atrial synchronous
biventricular pacing.
Follow-up and study endpoints. Response to CRT was
defined by LV reverse remodeling as a 15% reduction in
LVESV) at 6 months. The primary endpoint was a com-
parison of response between the TARGET and control
groups. Secondary endpoints included clinical response
(defined as 1 improvement in NYHA functional class),
all-cause mortality, and the combined endpoint of all-cause
mortality and heart failure–related hospitalization.
Statistical analysis. Analyses were conducted according to
the intention-to-treat principle. The study had a statistical
power of 80% to identify a 20% absolute difference in
response rates between the 2 groups given a conventional
1-sided  value of 0.05. Statistical analysis was performed
Baseline Characteristics ofP ti nts in Both Randomized GroupsTable 1 B seline Characteristic ofPatients in Both Randomized Groups
Target Group
(n  110)
Control Group
(n  110)
Age, yrs 72 (65/76) 72 (64/80)
Male 85 (77) 88 (80)
NYHA functional class III/IV 95/15 93/17
Ischemic cardiomyopathy 62 (56) 61 (56)
Diabetes mellitus 30 (27) 29 (26)
Previous CABG 35 (32) 29 (26)
Previous MI 56 (51) 58 (53)
QRS duration, ms 157 (148/170) 159 (146/170)
LVEDV, ml 198 (152/231) 198 (166/221)
LVESV, ml 152 (118/183) 149 (130/176)
LVEF, % 23 (19/28) 24 (18/29)
Moderate/severe
mitral regurgitation
24 (22) 27 (25)
ACEI 80 (73) 77 (70)
ARB 24 (22) 26 (24)
ACEI or ARB 104 (95) 103 (94)
Beta-blockers 78 (71) 77 (70)
Spironolactone 63 (57) 59 (54)
Loop diuretics 100 (100) 100 (100)
LV filling time, ratio 0.41 (0.37/0.46) 0.40 (0.35/0.46)
IVMD, ms 43 (22/61) 41 (25/57)
AS-P wall delay, ms 187 (101/320) 177 (120/336)
Values are median (25th/75th percentile) or n (%).
ACEI angiotensin-converting enzyme inhibitors; ARB angiotensin receptor blockers; AS-P
nteroseptal-posterior; CABG  coronary artery bypass grafting; IVMD  interventricular mechan-
cal delay; LV  left ventricular; LVEDV  left ventricular end-diastolic volume; LVEF  left
ventricular ejection fraction; LVESV  left ventricular end-systolic volume; MI  myocardial
infarction; NYHA  New York Heart Association.
i
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for Windows, GraphPad, San Diego, California, and SPSS
statistical software, version 17.0, SPSS Inc., Chicago, Illi-
nois). Continuous variables are expressed as mean  SD.
Categorical variables are presented as frequencies and per-
centages. Differences were assessed using paired and un-
paired Student t tests for continuous variables, the chi-
square test for trend for ordinal variables, or the Fisher exact
test for unordered categorical variables as appropriate. A p
value of 0.05 was considered statistically significant. Uni-
variable and, to adjust for age, sex, and other baseline
parameters, multivariable logistic regression analyses were
used to assess the relationship of LVESV change at
follow-up to the LV lead position, scar presence at the LV
pacing site, and baseline LV dyssynchrony. Kaplan-Meier
curves were plotted to describe all-cause mortality with and
without combining with cause-specific hospitalization, and
the log-rank test used to compare the groups.
Results
Patient population and baseline characteristics. No sta-
tistically significant differences were produced by the ran-
domization process in any of the recorded baseline charac-
teristics between patients in the TARGET and control
groups (Table 1). The implantation of the LV lead failed in
Figure 2 Consort Diagram for the TARGET Study
Consort diagram for the TARGET study illustrating the recruitment, group allocation
mary endpoint were those who failed to receive a cardiac resynchronization therap
and those patients lost to follow-up. All other patients were included on an intenti7 patients (3%) (4 in the TARGET group), despite repeated
attempts, due to coronary sinus dissection (n 2), failure to
ntubate the coronary sinus (n  2), absence of an appro-
riate coronary sinus tributary (n  2), and intractable
phrenic nerve stimulation (n  1). Eleven patients (5%) (6
in the TARGET group) did not return for echocardio-
graphic and clinical assessment at 6 months. Three patients
in the TARGET group and 4 patients in the control group
died within 6 months of device implantation and were
classified as nonresponders. The proportion of patients
receiving defibrillators was similar in each group (control vs.
TARGET, 39.4% vs. 43.7%; p  0.549). For the primary
and secondary endpoints, data were excluded for all patients
lost to follow-up in both groups and from 1 patient in each
of the assigned groups who died between randomization
and scheduled device therapy (time delay, 3 and 5 days,
respectively). Data for all other patients were included on an
intention-to-treat principle, giving 103 patients in the
TARGET and 104 patients in the control groups (Fig. 2).
Survival and heart failure–related hospitalization data were
available for all participants.
LV lead targeting and procedural success. There were no
differences in the distribution of the latest segment of activa-
tion or the overall LV lead position between the groups.
However, on an individual basis, when relating the LV lead
w-up, and analysis of all patients. Patients excluded from the analysis of the pri-
) device due to death between randomization and scheduled device implantation
eat basis. LV  left ventricular., follo
y (CRT
on-to-tr
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group, there more concordant leads, a similar number of
adjacent leads, and fewer remote leads. The total procedural
time was similar in the 2 groups, although in the target
group, screening time was longer. Implant-related compli-
cations were similar in both groups (Table 2).
Primary endpoint: echocardiographic response. In the
TARGET group after 6 months of CRT, 70% of the
subjects (n  72) were classified as responders compared
with 55% of the subjects (n  57) in the control group (p 
0.031). The absolute difference in primary response rates is
15% (95% confidence interval: 2% to 28%), and the number
need to treat by using a targeted approach to LV lead
placement to gain an additional responder is 6.6 (95%
confidence interval: 4 to 49). The changes in LV end-
diastolic volume, LVESV, and LV ejection fraction between
both the groups at baseline and follow-up are shown in
Figure 3 and Table 3.
econdary endpoints. In the TARGET group, NYHA
Distribution of Latest Site of Activation, LV LeadComplications, and Proc dural Ch racteristics BTable 2 Distribu ion of L test Site of ActivaComplications, and Procedural Cha
Latest site of activation, % (% basal/mid)
Inferior
Posterior
Lateral
Anterior
Anteroseptal
Inferoseptal
LV lead position, % (% basal/mid/apical)
Inferior
Posterior
Lateral
Anterior
Failed implantation
Relationship of LV lead to late site
Concordant
Adjacent
Remote
Failed implantation
Scar at LV lead site
Implant-related complications
Total
Failure to implant LV lead
LV lead displacement requiring repositioning
Device infection requiring extraction and reimplantation
Pneumothorax requiring chest drain
Myocardial perforation
Phrenic nerve stimulation (LV lead reposition)
Procedural characteristics
Procedural length, min
Screening time, min
Screening dose, mGy/cm2
Values are absolute numbers (%) or mean  SD.
LV  left ventricular.unctional class improved by1 in 83% of patients (n 85) dcompared with only 65% of patients (n  68) in the control
roup (p  0.003). NYHA functional class was unchanged
n 10 patients and deteriorated in 8 patients in the
ARGET group; in the control group, NYHA functional
lass was unchanged in 24 patients and deteriorated in 12
atients. The improvement in the 6-min walk test perfor-
ance and Minnesota Living with Heart Failure Question-
aire scores was greater in the TARGET group (Table 3).
Over a 2-year follow-up period, there were 22 deaths
10%) in total and 18 episodes (8%) of heart failure–related
ospitalization. The 2-year all-cause mortality rates were
imilar in the TARGET and control groups (log-rank test,
 0.301). The rate of the combined endpoint was,
owever, higher in the control group (log-rank test, p 
.031) (Fig. 4) driven by a higher rate of heart failure–
elated hospitalization. In the entire cohort, long-term
ndpoints were evaluated according to the LV lead position
nd the presence of scar at the LV pacing site. Four of the
eaths occurred in patients who did not receive CRT due to
ition, Implant-Relateden Both Treated GroupsLV Lead Position, Implant-Related
ristics Between Both Treated Groups
Target Group
(n  103)
Control Group
(n  104) p Value
0.962
13 (13) [4/9] 14 (15) [5/9]
38 (39) [14/24] 41 (43) [15/26]
32 (33) [13/19] 31 (32) [11/20]
9 (9) [3/6] 7 (7) [3/4]
4 (4) [1/3] 4 (4) [1/3]
4 (4) [1/3] 3 (3) [0/3]
0.442
12 (12) [4/7/1] 6 (6) [1/4/1]
5 (36) [12/20/3] 38 (40) [14/22/2]
6 (47) [16/29/1] 47 (49) [13/31/3]
3 (3) [1/2] 6 (6) [2/4]
4 (4) 3 (3)
0.011
61 (63) 45 (47)
25 (26) 28 (29)
10 (10) 24 (25)
4 (4) 3 (3)
8 (8) 16 (15) 0.131
0.993
13 (13) 14 (13)
4 (4) 3 (3)
5 (5) 6 (6)
1 (1) 1 (1)
1 (1) 1 (1)
1 (1) 1 (1)
1 (1) 2 (2)
139 36 138 42 0.823
25 14 19 13 0.033
133 107 91 69 0.024Posetwetion,
racte
3
4eath before implantation or failure to implant an LV lead.
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(5%) and 12 combined deaths and heart failure–related
hospitalizations (10%). This was much lower than patients
with an adjacent LV lead (5 [9%] and 12 [21%], respec-
tively) or a remote LV lead (7 [24%] and 12 [15%],
respectively) (Fig. 5). In patients in whom scar was present
at the LV pacing site, there were 6 deaths (29%) and 9
combined deaths and heart failure–related hospitalizations
(38%). This was much higher than in patients with no scar
at the LV pacing site in whom there were 12 deaths (6%)
and 9 combined deaths and heart failure–related hospital-
izations (5%) (Fig. 6).
Univariable and multivariable regression analyses. Uni-
variable and multivariable regression analyses were used to
determine which parameters predict LV reverse remodeling
(Table 4), and increasing age, male sex, LV lead concor-
dance, presence of scar at the LV pacing site, and dyssyn-
chrony but not QRS duration or etiology were significantly
associated with response to CRT.
Discussion
The present study prospectively demonstrates the feasibility
and improved outcome associated with a targeted approach
to LV lead placement during CRT implantation. Greater
LV reverse remodeling, better clinical response, and a lower
Echocardiographic and Clinical Parametersat Baseline and Follow-UpBetwe n Both Rand mized Groups
Table 3
Echo ardiographic and Clinical Parameters
at Baseline and Follow-Up
Between Both Randomized Groups
Target
(n  103)
Control
(n  104) p Value
NYHA functional class
Baseline 3.1 0.3 3.1 0.3
Follow-up 2.0 0.7 2.3 0.7
Change 1.1 0.7 0.8 0.7 0.002
6MWT, m
Baseline 222 92 229 95
Follow-up 282 101 268 112
Change 61 76 38 76 0.011
MLHFQ
Baseline 55 21 53 20
Follow-up 33 21 38 22
Change 22 20 16 19 0.024
LVEDV, ml
Baseline 202 66 200 58
Follow-up 160 51 176 56
Change 41 34 23 23 0.001
LVESV, ml
Baseline 157 56 154 52
Follow-up 111 43 128 50
Change 46 33 26 23 0.001
LVEF, %
Baseline 23 6 23 7
Follow-up 31 9 28 10
Change 8 7 5 8 0.001
Values are mean  SD.Figure 3 Comparison of LV Volumes and Function at
Baseline and 6-Month Follow-up Between Both Groups
Comparison of changes in left ventricular (LV) volumes and LV function between
both study groups at baseline and at 6-month follow-up showing greater improve-
ments in LV reverse remodeling and improvements in ejection fraction in the
TARGET population. LVEF  left ventricular ejection fraction; LVEDV  left ventricu-
lar end-diastolic volume; LVESV  left ventricular end-systolic volume. 6MWT 6-min walk test; MLHFQMinnesota Living With Heart Failure Questionnaire; other
bbreviations as in Table 1.
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related hospitalization (largely driven by the latter) was
found with guided LV lead implantation using echocardio-
graphic speckle-tracking 2D radial strain imaging. Multi-
variate analysis suggests that the greatest benefit is demon-
strated in patients with a concordant LV lead at sites free of
scar, with significantly lower responses in patients with
either an LV lead remote to the latest site of contraction or
when pacing scar.
A number of studies reported that CRT is superior to
Figure 4 Kaplan-Meier Curves
Comparing Both Randomized Groups
Kaplan-Meier curves for the outcomes of all-cause mortality and the combined
endpoint of all-cause mortality and heart failure–related hospitalization for both
groups are shown. There were no significant differences in all-cause mortality,
although there were significant differences in the combined endpoint driven by
lower rates of heart failure–related hospitalization. CRT  cardiac resynchroni-
zation therapy.optimal medical treatment in patients with advanced heartfailure (1,2,21,22). Consistent in all of these reports is a
failure to derive any significant benefit in a substantial
minority of all recipients of device therapy. A number of
factors have been implicated in this lack of response to CRT
including mechanical dyssynchrony, but defining the abnor-
mal LV function at echocardiography has not enhanced
clinical response. However, the underlying pathophysiology
of bundle branch block and contractile dysfunction results in
Figure 5 Kaplan-Meier Curves Comparing
Groups According to LV Lead Position
Subgroup analysis of all patients across both groups was conducted to assess
the effect of left ventricular (LV) lead position on outcomes. Kaplan-Meier
curves for the outcomes of all-cause mortality and the combined endpoint of
all-cause mortality and heart failure–related hospitalization for all 3 groups
(concordant, adjacent, and remote LV lead positions) are shown. There were
significant differences in all-cause mortality and the combined endpoint in
all 3 groups.
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both early and delayed activation within the left ventricle
leading to wasted work, increased end-systolic volume, wall
stress, and a further decline in myocardial efficiency (23–25).
The reversal of these deleterious effects through coordina-
tion of myocardial contraction is the primary target of CRT.
However, the extent to which this may be achieved has not
been previously assessed in a randomized trial of LV lead
Figure 6 Kaplan-Meier Curves Comparing Groups According
to Presence or Absence of Scar at LV Pacing Site
Subgroup analysis of all patients across both groups was conducted to
assess the effect of the presence or absence of scar at the left ventricular
(LV) pacing site. Kaplan-Meier curves for the outcomes of all-cause mortal-
ity and the combined endpoint of all-cause mortality and heart failure–
related hospitalization are shown. There were significant differences in all-
cause mortality and the combined endpoint according to the presence or
absence of scar at the LV pacing site.location and the underlying myocardial substrate with re-spect to the delayed LV segments and distribution of
myocardial scar.
The conventional approach to resynchronization has been
to direct the LV lead to the lateral and posterior wall based
on the benefit shown in early hemodynamic studies and the
observation that delayed segments predominate at these
sites. However, recent data support a more individualized
approach to LV lead placement with significant interindi-
vidual and intraindividual variation in the optimal LV lead
position (9,11). In addition to such acute hemodynamic
data, a number of reports using imaging techniques dem-
onstrated that pacing the latest segment of contraction leads
to more energetically efficient ventricular ejection, greater
LV reverse remodeling, improved survival, and reduced
heart failure–related hospitalization compared with those
patients with discordant pacing leads (12,26,27). Similarly,
patients with extensive scar or scar in the region of the LV
pacing site show lower response rates to CRT and a poorer
prognosis (15,28). Deformation imaging by speckle-
tracking radial strain imaging can identify myocardial scar,
and in this study, we used a value of 10% to define scar
because this figure has been derived and validated by our
group in a CRT population and related to LV lead position
(19). Avoiding nonviable myocardium is important, but
being able to identify the optimal pacing site but not reach
it via a suitable coronary vein is an inherent limitation of
transvenous CRT implantation (29). In this study, the
targeted approach achieved the aim of a higher proportion
of concordant LV leads with fewer remote leads and leads
over regions of scar with low lead complication rates.
Furthermore, in this randomized study, subgroup analyses
confirm previous reports that the greatest clinical response is
seen in patients with a concordant LV lead, together with
Univariate and Multivariate Regression Analyseso the Effect of Each Variable onLV Revers Remodeling at 6 Months
Table 4
Univariate nd Multivariate Regres ion Analyses
on the Effect of Each Variable on
LV Reverse Remodeling at 6 Months
OR 95% CI p Value
Univariate regression analysis
Age 1.05 1.01–1.80 0.007
Male 2.09 0.99–4.43 0.054
Ischemic etiology 1.74 0.97–3.12 0.064
QRS duration 1.00 0.98–1.01 0.474
No scar at LV pacing site 2.40 1.02–5.70 0.046
Dyssynchrony 5.51 2.90–10.40 0.010
Concordant LV lead 5.30 2.80–9.96 0.010
Multivariate regression analysis
Age 1.06 1.01–1.11 0.018
Male 2.85 1.02–7.96 0.045
Ischemic etiology 1.54 0.69–3.43 0.293
QRS duration 0.99 0.97–1.01 0.224
No scar at LV pacing site 3.06 1.01–9.26 0.048
Dyssynchrony 5.95 2.78–12.7 0.009
Concordant LV lead 4.43 2.09–9.40 0.009CI  confidence interval; LV  left ventricular; OR  odds ratio.
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of death and heart failure–related hospitalization.
Despite targeting, the limitations of coronary venous
anatomy appear to have restricted concordance to only two
thirds of patients, and 8% of all patients still had LV lead
placement at areas of scar. Our data suggest that as many as
one third of all patients may require additional assessment
to guide and achieve optimal LV lead placement including
coronary venous anatomy and precise delineation of scar,
areas of late contraction, or late electrical activation. Al-
though this approach may restrict implantation to more
specialized centers, it may enable CRT to achieve its full
potential in the therapeutic armamentarium of advanced
heart failure. It is also important to identify those
patients in whom it will not be possible to place the LV
lead appropriately to enable alternative routes to be
considered. The present study demonstrated that a rela-
tively simple investigative tool can be used to guide LV
lead placement with significant benefits over and above
usual LV lead placement.
Study limitations. Two-dimensional radial strain imaging
was used to determine the optimal LV pacing site based on
the delayed segment and lowest amplitude associated with
the highest negative predictive value in those being consid-
ered for CRT. However, radial strain may not be the best
technique, and further work related to examining changes in
circumferential strain or combined patterns of strain may
have had superior results. Furthermore, 3-dimensional
speckle tracking, which was not widely available at the
commencement of this study, may better define the optimal
site with greater potential for coregistration of different
imaging techniques. Importantly, not everyone will be able
to undergo speckle-tracking echocardiography as 11% of
patients were excluded from this study due to inadequate
image quality. Dyssynchrony is one of the major underlying
abnormalities within the left ventricle of this group of
patients with heart failure, and yet despite the results of the
PROSPECT (Predictors of Response to Cardiac Resyn-
chronization Therapy) study, it is clear that adequate and
clinically relevant characterization of such abnormal con-
traction is not readily offered by a single investigation.
Speckle-tracking echocardiography offers additional infor-
mation regarding myocardial function and may predict the
benefit from CRT by radial strain analysis (13,30–32), but
further studies using more recent technological develop-
ments may increase our understanding of how to use device
therapy to treat ventricular dysfunction. In our study, we
made no attempt to pre-select patients on the basis of
dyssynchrony parameters, nor was consideration given to
the extent of total scar burden. The presence of both of
these parameters would tend to reduce the overall benefit,
although this would be distributed in both groups. CRT
response may therefore be enhanced by integrating mea-
sures of dyssynchrony and total scar burden with a targeted
approach to lead placement, and such an approach should be
tested in future studies.Conclusions
The TARGET study is the first randomized, controlled
study to demonstrate the benefit of a targeted approach to
LV lead placement in CRT, resulting in significant benefit
defined by LV reverse remodeling, clinical status, and the
long-term endpoint of combined death and heart failure–
related hospitalization. The study prospectively confirms the
importance of the LV lead position in CRT outcomes and
demonstrates the feasibility of LV lead targeting using
speckle-tracking radial strain imaging as a modality to guide
lead placement. Given this randomized trial’s observed
number needed to treat for a response of approximately 7
(95% confidence interval: 4 to 49), an individualized ap-
proach to LV lead placement should be considered in all
patients undergoing CRT for advanced heart failure to yield
a significant improvement over current routine practice.
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